Duncker Streett & Co. Inc. Sells 620 Shares of Align Technology, Inc. (NASDAQ:ALGN)

Duncker Streett & Co. Inc. decreased its stake in Align Technology, Inc. (NASDAQ:ALGN) by 86.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101 shares of the medical equipment provider’s stock after selling 620 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Align Technology were worth $28,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ALGN. Raymond James Trust N.A. boosted its stake in Align Technology by 39.4% in the 1st quarter. Raymond James Trust N.A. now owns 934 shares of the medical equipment provider’s stock valued at $407,000 after buying an additional 264 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Align Technology by 11.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 180,978 shares of the medical equipment provider’s stock worth $78,911,000 after acquiring an additional 18,153 shares in the last quarter. Prudential PLC bought a new stake in Align Technology during the 1st quarter worth approximately $955,000. Cetera Investment Advisers grew its position in Align Technology by 4.9% during the 1st quarter. Cetera Investment Advisers now owns 1,713 shares of the medical equipment provider’s stock worth $747,000 after acquiring an additional 80 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in Align Technology by 17.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 526 shares of the medical equipment provider’s stock worth $229,000 after acquiring an additional 77 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Insider Buying and Selling

In other news, EVP Emory Wright sold 2,524 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the completion of the transaction, the executive vice president now owns 709 shares in the company, valued at approximately $203,802.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Align Technology news, Director Joseph Lacob sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total transaction of $4,548,300.00. Following the completion of the sale, the director now directly owns 131,994 shares in the company, valued at $40,023,220.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Emory Wright sold 2,524 shares of Align Technology stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total transaction of $725,523.80. Following the completion of the sale, the executive vice president now owns 709 shares of the company’s stock, valued at $203,802.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,524 shares of company stock valued at $8,403,924. 0.64% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Leerink Partnrs restated a “market perform” rating on shares of Align Technology in a research report on Monday, February 26th. SVB Leerink initiated coverage on Align Technology in a research report on Monday, February 26th. They set a “market perform” rating and a $310.00 price target on the stock. The Goldman Sachs Group increased their price objective on Align Technology from $197.00 to $225.00 and gave the company a “sell” rating in a research report on Friday, February 2nd. Piper Sandler increased their price objective on Align Technology from $335.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, March 14th. Finally, UBS Group increased their price objective on Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a research report on Monday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Align Technology currently has a consensus rating of “Moderate Buy” and an average target price of $339.91.

Align Technology Trading Down 1.6 %

Shares of Align Technology stock opened at $300.14 on Thursday. The company has a market capitalization of $22.59 billion, a PE ratio of 51.57, a PEG ratio of 5.46 and a beta of 1.65. Align Technology, Inc. has a 12 month low of $176.34 and a 12 month high of $413.20. The stock’s fifty day simple moving average is $312.61 and its 200 day simple moving average is $269.97.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $1.91 EPS for the quarter, topping the consensus estimate of $1.78 by $0.13. The business had revenue of $956.73 million for the quarter, compared to the consensus estimate of $928.57 million. Align Technology had a return on equity of 13.88% and a net margin of 11.52%. Analysts predict that Align Technology, Inc. will post 7.69 EPS for the current fiscal year.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.